What does Traws Pharma do and what are its main business segments?

What factors drove the changes in Traws Pharma's revenue and profit?

What is the market's earnings forecast for Traws Pharma next quarter?

Did Traws Pharma beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Traws Pharma year over year?

What is Traws Pharma's gross profit margin?

What guidance did Traws Pharma's management provide for the next earnings period?

What were the key takeaways from Traws Pharma’s earnings call?

- **Clinical Trial Progress**: Phase II COVID studies expected to report by year-end 2025; bird flu trial deferred but ready for quick启动.
- **Financial Highlights**: Reduced expenses (R&D -42.5%, G&A -15% YoY), net loss of $0.9M due to one-time charge.
- **Market Potential**: $1.5B for COVID drug in underserved patients; bird flu preparedness with BARDA discussions.

**【CEO Summary Section】**
- **COVID Program Reprioritization**: Submitted Phase II studies for ratutrelvir in COVID patients, targeting results by year-end 2025. Planning a single-arm study for PAXLOVID-ineligible patients, a $1.5B market opportunity.
- **Influenza Program Updates**: Deferred bird flu Phase II study due to low incidence but secured regulatory approvals in Australia and South Korea for rapid initiation. Engaging with BARDA for tivoxavir marboxil stockpiling.
- **Legacy Assets**: Rigosertib shows 80% response rate in RDEB SCC, seeking partnerships.

**【CFO Financial Commentary】**
- **Cash Position**: $13.1M as of Q2 2025, down from $21.3M in Q4 2024.
- **Revenue and Expenses**: $2.7M revenue (vs. $57K), R&D down 42.5% YoY to $2.3M, G&A down 15% YoY to $1.7M.
- **Net Loss**: $0.9M (vs. $123.1M in Q2 2024, driven by one-time R&D charge).

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

TRAW

TRAW fundamentals

You can ask Aime